Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Ketoconazole

Ketoconazole

Ketoconazole is a synthetic imidazole antifungal agent used to treat a wide range of fungal infections, including candidiasis, blastomycosis, coccidioidomycosis, and histoplasmosis.
It works by inhibiting the fungal enzyme lanosterol 14-alpha-demethylase, which is essential for the production of ergosterol, a key component of the fungal cell membrane.
Ketoconazole is available in topical, oral, and intravenous formulations, and is commonly prescribed for both systemic and localized fungal infections.
Reserchers can utilize PubCompare.ai, an AI-driven platform, to optimize Ketoconazole research by locating relevant protocols from literature, preprits, and patents, and leveraging AI-driven comparisons to identify the best protocolls and products for their projects.
This can help improve reproducibility and accuaracy in Ketoconazole-related studies.

Most cited protocols related to «Ketoconazole»

1
Antifungal Bioassay of Aspergillus fumigatus
Cited 11 times
For the antifungal bioassays, two strains of Aspergillus fumigatus were used: Aspergillus fumigatus (ATCC 204305), and Aspergillus fumigatus (human clinical isolate). The organisms are deposited at the Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research “Siniša Stankovic,” Belgrade, Serbia.
The micromycetes were maintained on malt agar and the cultures were stored at 4°C and sub-cultured once a month. The antifungal assay was carried out by a modified microdilution technique [45 (link),46 (link)] in order to determine the minimum inhibitory (MIC) and minimum fungicidal concentrations (MFC) of the examined compounds. Briefly, the fungal spores were washed from the surface of agar plates with sterile 0.85% saline containing 0.1% Tween 80 (v/v). The spore suspension was adjusted with sterile saline to a concentration of approximately 1.0×105 in a final volume of 100 μL per well. The examined compounds were dissolved in 5% of DMSO, serially diluted in broth malt medium after which fungal inoculum was added. The microplates were incubated for 72 h at 28°C. The lowest concentrations without visible growth (in a binocular microscope) were defined as MICs. The fungicidal concentrations (MFCs) were determined by serial sub cultivation of 2 μL of the wells content into microtiter plates containing 100 μL of broth per well and further incubation for 72 h at 28°C. The lowest concentration with no visible growth was defined as MFC indicating 99.5% killing of the original inoculum. The commercial antifungals econazole and ketoconazole were used as positive controls.
Kritsi E., Matsoukas M.T., Potamitis C., Detsi A., Ivanov M., Sokovic M, & Zoumpoulakis P. (2019). Novel Hit Compounds as Putative Antifungals: The Case of Aspergillus fumigatus. Molecules, 24(21), 3853.
Full text: Click here
Publication 2019
Agar Antifungal Agents Aspergillus fumigatus Biological Assay Biopharmaceuticals Econazole Homo sapiens Industrial Fungicides Ketoconazole Microscopy Minimum Inhibitory Concentration Plant Physiological Phenomena Psychological Inhibition Saline Solution Spores Spores, Fungal Sterility, Reproductive Strains Sulfoxide, Dimethyl Tween 80 Tween 85
2
Phenotypic Profiling of Candida parapsilosis
Cited 9 times

Candida parapsilosis strains (Table S1) were grown in YPD medium (1% yeast extract, 2% peptone, 2% glucose) at 30°C. For colony selection 2% agar was added. To select for transformants, nourseothricin (Werner Bioagents Jena, Germany) was added to YPD agar at a final concentration of 200 µg ml−1. Transformants containing the LEU2 and HIS1 markers were selected on synthetic complete (SC; 0.19% yeast nitrogen base without amino acids and ammonium sulphate, 0.5% ammonium sulphate, 2% dextrose, 0.075% mixture of amino acids, 2% agar) media without leucine or histidine. For biofilm formation, C. parapsilosis was grown in synthetic defined (SD) medium (0.67% yeast nitrogen base) containing 50 mM glucose. C. albicans was grown in Spider media (1% nutrient broth, 1% mannitol, 0.2% potassium phosphate). The media used for phenotype screening is shown in Table S2. All deletion strains were grown in 96 well plates in YPD media at 30°C overnight. The cultures were then diluted 1∶100 into a new 96 well plate containing fresh YPD media. The strains were then pinned onto agar plates using a 48 pin bolt replicator. Plates were incubated at 30°C and photographed after 2 and 3 days of growth. Each knockout was scored on growth in comparison to the control strains (CLIB214 and CPRI) on the same media, where −4 indicates a severe growth defect, −3, −2, and −1 indicate strong, moderate and marginal growth defects, 0 is similar to the control strains, and +1 is stronger growth than control strains. Scores were assigned only where the two independent replicates had the same behavior. Screens were repeated at least twice. Growth on different chemical concentrations (e.g. CuCl2, ketoconazole) were combined to give a single score (see Table S2). Deletion strains with interesting phenotypes were further validated by plating exact numbers of cells in decreasing concentration on test media. Control strains were included in each plate. Scores were converted to a Heatmap using Bioconductor [114] (link).
Holland L.M., Schröder M.S., Turner S.A., Taff H., Andes D., Grózer Z., Gácser A., Ames L., Haynes K., Higgins D.G, & Butler G. (2014). Comparative Phenotypic Analysis of the Major Fungal Pathogens Candida parapsilosis and Candida albicans. PLoS Pathogens, 10(9), e1004365.
Full text: Click here
Publication 2014
Agar Amino Acids Amino Acids, Basic Biofilms Candida albicans Candida parapsilosis cupric chloride Deletion Mutation Glucose Histidine Ketoconazole Leucine Mannitol Nitrogen Nitrogen-19 Nourseothricin Nutrients Peptones Phenotype potassium phosphate Spiders Strains Sulfate, Ammonium Yeasts
3
Generating Neurocortical and Oligocortical Spheroids
Cited 8 times
Neurocortical spheroids were generated from human pluripotent stem cells as previously described with variations noted below3 (link).
To pattern neurocortical spheroids, pluripotent stem cell colonies cultured on vitronectin (Gibco #A14700) were lifted using dispase (Gibco #17105–041) at 37°C for 10 minutes. Intact colonies were transferred to individual low-adherence V-bottom 96-well plates (S-Bio Prime #MS-9096VZ) in 200μl Spheroid Starter media with 10μM Rock inhibitor Y-27632 (Calbiochem #688001), 10 μM Dorsopmorphin (Sigma #P5499), and 10 μM SB-431542 (Sigma #S4317). Spheroid Starter media was DMEM/F12 (Invitrogen #11320–033) containing 20% Knock out Serum (Invitrogen #12587–010), Non-essential amino acids (Invitrogen #11140050), Glutamax (Invitrogen #35050061), β-mercaptoethanol and 100U/ml Penicillin/Streptomycin. The same media without rock inhibitor was used for the next five days, after which the media was changed to Neurobasal-A based spheroid media. Neurobasal-A spheroid media was Neurobasal-A medium (Invitrogen #10888022) with added B-27 serum substitute without vitamin A (Invitrogen #12587), Glutamax (Invitrogen #35050061) and 100U/ml Penicillin/Streptomycin. From day 7–25, 20ng/ml FGF-2 (R&D systems #233-FB-25/CF) and 10ng/ml EGF (R&D systems #236-EG-200) were added to the media. Spheroids were cultured in 96-well plates through day 25, with daily half-media changes. On day 25, spheroids were transferred to ultra-low attachment 6-well plates (Corning #CLS3471) at a density of 8–10 spheroids per well and cultured thus through the remainder of the protocol. Also from this point forward 1% Geltrex (Invitrogen # A15696–01) was added to the Neurobasal-A spheroid media. Neural differentiation was induced between days 27 and 41 by supplementing Neurobasal-A spheroid media with 20ng/ml BDNF (R&D systems #248-BD) and 20ng/ml NT-3 (R&D systems #267-N). Half media changes were performed every other day between days 17 and 41.
To generate oligocortical spheroids, beginning on day 50, 10 ng/ml platelet-derived growth factor-AA (PDGF-AA, R&D Systems #221-AA-050) and 10 ng/ml insulin-like growth factor-1 (IGF-1, R&D Systems #291-G1–200) were added to the every-other-day media changes for 10 days. Next, on day 60, 40 ng/ml 3,3’,5-triiodothronine (T3, Sigma #ST2877) was added to the every-other-day media changes for 10 days. When used, small molecules were supplemented during this period. 4μM Ketoconazole and 2 μM Clemastine were added in lieu of T3. GSK2656157 was added in addition to T3.
After day 70, spheroids were matured and maintained in Neurobasal-A spheroid media with every-other-day media changes until completion of the experiment.
Madhavan M., Nevin Z.S., Shick H.E., Garrison E., Clarkson-Paredes C., Karl M., Clayton B.L., Factor D.C., Allan K.C., Barbar L., Jain T., Douvaras P., Fossati V., Miller R.H, & Tesar P.J. (2018). Induction of Myelinating Oligodendrocytes in Human Cortical Spheroids. Nature methods, 15(9), 700-706.
Publication 2018
2-Mercaptoethanol 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide Amino Acids, Essential Clemastine dispase Fibroblast Growth Factor 2 GSK2656157 Homo sapiens IGF1 protein, human Ketoconazole Nervousness PDGF AA Penicillins Pluripotent Stem Cells Serum Streptomycin Vitamin A Vitronectin Y 27632
4
Comparing Self-Reported and Pharmacy-Recorded Drug Use
Cited 7 times
The linked information relevant to this study consisted of anonymized identifier codes, ATC codes, dispensing dates, date of entry in the IADB database, sex and age at the time of the first visit at entry to the cohort. The very first interview with the Lifelines Cohort Study participant was considered the baseline measurement and only the data of the baseline measurements (entry period) were used in the comparison of the two databases.
All drugs grouped at a second level of ATC coding were examined in the study. Besides the second level ATC codes, some specific drugs at the chemical level were included in the study. A top list of the several most commonly used drugs in the Netherlands including omeprazole, psylla seeds, macrogol, calcium, hydrochlorothiazide, metoprolol, enalapril, simvastatin, ketoconazole, triamcinolone, clobetasol, levothyroxine, oxazepam, temazepam, paroxetine, fluticasone, mometasone, salbutamol, salmeterol/fluticasone, desloratadine, artificial tears, carbasalate ca., diclofenac and ibuprofen was also examined.
The program SQL Server was used to compare the records of drugs for each participant. The acquired data was then categorized in true positives, true negatives, false positives (FPs) and false negatives (FNs). These values were given in cross-tables, which were used to calculate the concordance. Each of the four cells in these cross-tables were required to have at least 5 participants. If the number of participants was lower than 5 in one or more cells, the drug group or specific drug was disregarded.
In order to address the possible underlying cause of a low agreement, the FNs and FPs were examined. Over-reporting represents the number of FPs. This means that a number of participants reported the use of a certain drug group, while at the same time the prescription was not registered in the pharmacy records. On the other hand, under-reporting represents the number of FNs. This means that the participants did not report the use of a certain drug group, while at the same time the prescription was registered in the pharmacy records. If a drug group or specific drug showed a poor agreement and at the same time a high over-reporting, it could indicate that the database with the self-reported data is better capable in recording the use of this specific drug (or drug group).
Sediq R., van der Schans J., Dotinga A., Alingh R.A., Wilffert B., Bos J.H., Schuiling-Veninga C.C, & Hak E. (2018). Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy database iaDB.nl: The PharmLines initiative. Clinical Epidemiology, 10, 981-989.
Publication 2018
Albuterol Calcium, Dietary Cells Clobetasol desloratadine Diclofenac Enalapril Fluticasone Fluticasone Salmeterol Hydrochlorothiazide Ibuprofen Ketoconazole Lubricant Eye Drops Metoprolol Mometasone Omeprazole Oxazepam Paroxetine Pharmaceutical Preparations Plant Embryos Polyethylene Glycols Simvastatin Temazepam Thyroxine Triamcinolone
5
Enzalutamide for Metastatic Prostate Cancer
Cited 7 times
Patients were eligible if they had histologically or cytologically confirmed adenocarcinoma of the prostate with documented metastases and had PSA progression, radiographic progression, or both in bone or soft tissue, despite receiving LHRH analogue therapy or undergoing orchiectomy, with a serum testosterone level of 1.73 nmol per liter (50 ng per deciliter) or less. Continued androgen-deprivation therapy was required. Previous antiandrogen therapy and concurrent use of glucocorticoids were permitted but not required. Eligible patients had not received cytotoxic chemotherapy, ketoconazole, or abiraterone acetate, had an Eastern Cooperative Oncology Group performance status grade of 0 or 1 (no symptoms or ambulatory but restricted in strenuous activities), and were either asymptomatic (score of 0 to 1) or mildly symptomatic (score of 2 to 3), as measured on the Brief Pain Inventory Short Form question 3 (on which scores range from 0 to 10, with higher scores indicating a greater severity of pain). Patients with visceral disease, including lung or liver metastases, were eligible, as were patients with New York Heart Association class I or II heart failure. Patients with a history of seizure or a condition that could confer a predisposition to seizure were excluded, although patients taking medications associated with lowering the seizure threshold were eligible.
From September 2010 through September 2012, patients were enrolled at 207 sites globally. All patients were randomly assigned to receive either oral enzalutamide (at a dose of 160 mg) or placebo once daily with or without food. Randomization was stratified according to the study site. Treatment continued until the occurrence of unacceptable side effects or confirmed radiographic progression and the initiation of chemotherapy or an investigational agent. Treatment discontinuation because of an increase in the PSA level alone was discouraged.
Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S., Iversen P., Bhattacharya S., Carles J., Chowdhury S., Davis I.D., de Bono J.S., Evans C.P., Fizazi K., Joshua A.M., Kim C.S., Kimura G., Mainwaring P., Mansbach H., Miller K., Noonberg S.B., Perabo F., Phung D., Saad F., Scher H.I., Taplin M.E., Venner P.M, & Tombal B. (2014). Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. The New England journal of medicine, 371(5), 424-433.
Publication 2014
Abiraterone Acetate Adenocarcinoma Androgen Antagonists Androgens Bones Congestive Heart Failure Disease Progression enzalutamide Food Glucocorticoids Gonadorelin Heart Ketoconazole Liver Lung Neoplasm Metastasis Neoplasms Orchiectomy Pain Patients Pharmaceutical Preparations Pharmacotherapy Placebos Prostate Seizures Serum Severity, Pain Susceptibility, Disease Testosterone Tissues X-Rays, Diagnostic

Most recents protocols related to «Ketoconazole»

1
Chronic Pain after Elderly Arthroplasty
Elderly patients who underwent lower extremity arthroplasty in Drum Tower Hospital Affiliated to Nanjing University Medical School from September 2020 to March 2021 were selected and followed up for postoperative pain assessment using the numerical rating scale NRS. The elderly osteoarthritis patients selected were all caused by joint degeneration rather than fractures or necrosis caused by other reasons. They were performed operations by the same group of doctors and operation method. All patients signed informed consent and were authorized by the ethics committee of Drum Tower Hospital Affiliated to Nanjing University Medical School (Nanjing, China, No. 2019-270-02). Inclusion criteria: (1) Age ≥ 65 years old; (2) American Society of Anesthesiologists (ASA) classification II–III; (3) Patients undergoing lower extremity arthroplasty; (4) Operation duration ≥ 60 min; (5) Patients recorded in electronic medical record system; (6) Patients agreed to participate in the study and signed the informed consent. Exclusion criteria: (1) With gene deficiency disease; (2) Having history of opioid abuse; (3) Using drugs that induce or inhibit liver isoenzymes (such as carbamazepine, quinidine, ketoconazole, etc.) in 4 weeks before operation; (4) Combined with peripheral neuropathy and psychiatric history, chronic pain and long-term opioid use history; (5) With poor body conditions affecting the perioperative pain evaluation; (6) Patients can’t cooperate and communicate with.
The patient's NRS score being ≥ 4 on the 90th day after operation was identified as having severe CPSP. A total of 10 patients were judged to have severe CPSP (group A). 10 patients hospitalized in the same period without chronic postsurgical pain (NRS score = 0 on the 90th day after operation) were randomly selected as the control group (group B).
Xu R., Jin Y., Tang S., Wang W., Sun Y.E., Liu Y., Zhang W., Hou B., Huang Y, & Ma Z. (2023). Association between single nucleotide variants and severe chronic pain in older adult patients after lower extremity arthroplasty. Journal of Orthopaedic Surgery and Research, 18, 184.
Full text: Click here
Publication 2023
Abuse, Opioid Aged Anesthesiologist Arthroplasty Carbamazepine Cardiac Arrest Chronic Pain Deficiency Diseases Degenerative Arthritides Ethics Committees, Clinical Fracture, Bone Genes Human Body Isoenzymes Ketoconazole Liver Lower Extremity Necrosis Opioids Pain Measurement Patients Peripheral Nervous System Diseases Pharmaceutical Preparations Physicians Postoperative Pain, Chronic Quinidine
2
Metabolic Stability Determination Using Hepatic Microsomes
The metabolic stability of test compounds was determined as described.57 (link),58 (link) Incubation and experimental conditions with human hepatic microsomal fractions (purchased from BD Gentest as a pooled batch from 6 donors) were as follows: microsomal proteins, 1 mg/mL; bovine serum albumin, 1 mg/mL; substrate, 5 μM; incubation duration, 20 min; cytochrome P-450 monooxygenases (CYPs) and flavin containing monooxygenases (FMOs) cofactor, 1 mM NADPH. Enzyme activity was stopped with 1 volume of acetonitrile. Ketoconazole at a final concentration of 1.5 μM (100-fold above its Ki for CYP3A4) was used for the specific and potent inhibition of enzyme reactions catalyzed by CYP3A4. For each test compound and for each microsomal preparation, three incubations were prepared: absolute reference in buffer (without enzyme material, i.e., microsomes); incubation without NADPH cofactor (with microsomal fractions); and incubation with NADPH (with microsomal fractions). For most compounds, biotransformation, as observed in hepatic microsomal fractions in the presence of the NADPH cofactor, consists of oxidative reactions catalyzed by either CYPs or FMOs. In these conditions, the percentage of total metabolism, which corresponds to oxidative metabolism, was determined as follows: [% total metabolism] ≈ [% oxidative metabolism] = [unchanged compound (UC) peak area − NADPH UC peak area + NADPH] × 100%, where NADPH corresponds to the enzyme cofactor for oxidation reactions catalyzed by either CYP or FMO.
Zhang J., Lair C., Roubert C., Amaning K., Barrio M.B., Benedetti Y., Cui Z., Xing Z., Li X., Franzblau S.G., Baurin N., Bordon-Pallier F., Cantalloube C., Sans S., Silve S., Blanc I., Fraisse L., Rak A., Jenner L.B., Yusupova G., Yusupov M., Zhang J., Kaneko T., Yang T.J., Fotouhi N., Nuermberger E., Tyagi S., Betoudji F., Upton A., Sacchettini J.C, & Lagrange S. (2023). Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents. Cell, 186(5), 1013-1025.e24.
Full text: Click here
Publication 2023
acetonitrile Biotransformation Buffers Cell Respiration Coenzymes Cytochrome P-450 CYP3A4 Cytochrome P-450 Monooxygenase dimethylaniline monooxygenase (N-oxide forming) Donors enzyme activity Enzymes Homo sapiens Ketoconazole Liver Diseases Metabolism Microsomes NADP Proteins Serum Albumin, Bovine
3
Fungal Keratitis Treatment in Rabbits

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Asepsis Aspergillus flavus benoxinate Candida albicans Chloramphenicol Cornea Corneal Stroma Epithelium Eye Drops Formalin Freezing Fungi Fusarium Human Body Infection Inflammation Intramuscular Injection Ketalar Ketamine Ketoconazole Microscopy Needles Operative Surgical Procedures Oryctolagus cuniculus Rabbits Sac, Conjunctival Saline Solution Strains Therapeutics Topical Anesthetics
4
Thermosensitive Gel for Corneal Antifungal

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Albinism Animal Ethics Committees Animals Antifungal Agents Cornea Ethics Committees Ethics Committees, Research Faculty Faculty, Pharmacy Fluorescein Humidity Ketoconazole Males New Zealand Rabbits Oryctolagus cuniculus Segment, Anterior Eye Slit Lamp Vision
5
Antifungal Efficacy of Thermosensitive Gel
Cited 2 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Agar Clinical Laboratory Services Diffusion Glucose Ketoconazole poly(ethylene glycol)-co-poly(ethyleneimine) Polylactic Acid-Polyglycolic Acid Copolymer Psychological Inhibition Solanum tuberosum Sterility, Reproductive Strains

Top products related to «Ketoconazole»

1
Ketoconazole by Merck Group
Sourced in United States, Germany, India, Sao Tome and Principe, United Kingdom, Macao, Israel
Ketoconazole is a laboratory product manufactured by Merck Group. It is an antifungal agent used for research and development purposes. The core function of Ketoconazole is to inhibit the synthesis of ergosterol, a key component of fungal cell membranes.
2
Quinidine by Merck Group
Sourced in United States, Germany, China, Japan, France
Quinidine is a pharmaceutical compound used as a laboratory reagent. It is a diastereomer of the alkaloid quinine and has a chemical structure that allows it to be used in various biochemical and analytical applications.
3
Sulfaphenazole by Merck Group
Sourced in United States, China, Germany
Sulfaphenazole is a laboratory reagent used in chemical synthesis and analysis. It is a sulfonamide compound with molecular formula C₁₄H₁₁N₃O₂S. Sulfaphenazole is commonly used as an analytical standard and in various organic reactions.
4
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
5
Fluconazole by Merck Group
Sourced in United States, Germany, United Kingdom, Brazil, Italy, Canada, Japan, Sao Tome and Principe, Hungary, Poland, France, Ireland, Spain, China, India
Fluconazole is a pharmaceutical product manufactured by Merck Group. It is an antifungal medication used to treat a variety of fungal infections. The core function of Fluconazole is to inhibit the growth and proliferation of fungal pathogens.
6
Amphotericin b by Merck Group
Sourced in United States, Germany, United Kingdom, Spain, Italy, Brazil, France, Japan, Poland, Austria, Australia, Switzerland, Macao, Canada, Belgium, Ireland, China, Sao Tome and Principe, Hungary, India, Sweden, Israel, Senegal, Argentina, Portugal
Amphotericin B is a laboratory reagent used as an antifungal agent. It is a macrolide antibiotic produced by the bacterium Streptomyces nodosus. Amphotericin B is commonly used in research and biomedical applications to inhibit the growth of fungi.
7
Furafylline by Merck Group
Sourced in United States, China
Furafylline is a laboratory compound used as a research tool. It is a selective inhibitor of the CYP1A2 enzyme, which is involved in the metabolism of various drugs and other substances. Furafylline is utilized in studies to investigate the role of CYP1A2 in drug interactions and pharmacokinetics.
8
Glucose 6 phosphate dehydrogenase by Merck Group
Sourced in United States, Germany, China, Canada, Macao, Australia, Sao Tome and Principe
Glucose-6-phosphate dehydrogenase is an enzyme that catalyzes the conversion of glucose-6-phosphate to 6-phosphoglucono-δ-lactone, the first step of the pentose phosphate pathway. This enzyme plays a crucial role in maintaining cellular redox balance and generating NADPH, which is essential for various cellular processes.
9
Phenacetin by Merck Group
Sourced in United States, China, Germany, United Kingdom, Poland
Phenacetin is a chemical compound used in the manufacturing of various pharmaceutical and laboratory products. It serves as a key ingredient in the production process. Phenacetin has specific functional properties that make it a valuable component in relevant applications, but a detailed description of its core function is beyond the scope of this response.
10
Chlorzoxazone by Merck Group
Sourced in United States, China, Germany, United Kingdom, Czechia
Chlorzoxazone is a laboratory chemical used as a reference standard. It is a crystalline solid with a molecular formula of C7H5ClNO. Chlorzoxazone is primarily used for analytical purposes and quality control in various industries.

More about "Ketoconazole"

Ketoconazole is a synthetic antifungal agent from the imidazole class, commonly used to treat a wide range of fungal infections, including candidiasis, blastomycosis, coccidioidomycosis, and histoplasmosis.
It works by inhibiting the fungal enzyme lanosterol 14-alpha-demethylase, which is essential for the production of ergosterol, a key component of the fungal cell membrane.
Ketoconazole is available in topical, oral, and intravenous formulations, and is often prescribed for both systemic and localized fungal infections.
Researchers can utilize PubCompare.ai, an AI-driven platform, to optimize their Ketoconazole research.
This tool can help locate relevant protocols from literature, preprints, and patents, and leverage AI-driven comparisons to identify the best protocols and products for their projects.
This can improve reproducibility and accurracy in Ketoconazole-related studies.
In addition to Ketoconazole, other antifungal agents like Quinidine, Sulfaphenazole, Fluconazole, and Amphotericin B may be used to treat fungal infections.
Researchers may also employ solvents like DMSO, or metabolic modulators like Furafylline and Glucose-6-phosphate dehydrogenase, in Ketoconazole-related experiments.
Furthermore, Phenacetin and Chlorzoxazone are sometimes used as probe substrates to assess the impact of Ketoconazole on drug metabolism.
By leveraging the insights from these related compounds and techniques, researchers can enhance the quality and effectiveness of their Ketoconazole-focused studies.